Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Seer, Inc.NASDAQ: SEER

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $2.13M fell 54.4% year over year, behind the -49.1% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 35.3% from the prior quarter. Over 3 fiscal years it compounded at -22.9% a year.

Context

  • Stock-based compensation amounted to 95.6% of revenue in FY2025, down 106.6 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -54.4% toward the trailing-twelve-month pace of -49.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.13M-35.3% QoQ
Last fiscal yearDec 2025
$15.41M-45.4% YoY
LTMMar 2026
$12.88M-49.1% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-54.4%——
1 year-45.4%——
3-year CAGR-22.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
15.41M USD
Year-over-year change
-45.4%
4-year CAGR
-12.2%

Stock-Based Compensation vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -49.1% is the 18th highest of 19, against a peer median of -5.6%.
  • Stock-based compensation amounts to 85.6% of revenue for SEER, versus a peer median of 62.1%.
SEER Competitors
Stock-Based Compensation for SEER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KYMRKymera Therapeutics, Inc.LTM Jun 2026$65.2M USD+11.7%+19.1%62.1%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$40.66M USD+8.7%+10.5%5.8%
LYELLyell Immunopharma, Inc.LTM Mar 2026$35.81M USD+19.3%—115500.0%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$34.28M USD-12.0%+8.8%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$25.38M USD+66.4%——
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$25.03M USD+73.0%+248.9%—
SANASana Biotechnology, Inc.LTM Mar 2026$24.1M USD-32.3%-12.7%—
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$19.52M USD+5.2%+17.4%45.4%
PHVSPharvaris N.V.LTM Sep 2026€17.97M EUR-7.1%+18.8%—
CCCCC4 Therapeutics, Inc.LTM Mar 2026$16.26M USD-43.8%-14.0%46.7%
SEERSeer, Inc.LTM Mar 2026$12.88M USD-49.1%-22.9%85.6%
QSIQuantum-Si incorporatedLTM Mar 2026$10.98M USD+14.3%-1.3%592.7%
PEPGPepGen Inc.LTM Mar 2026$10.03M USD-22.0%+30.6%—
STTKShattuck Labs, Inc.LTM Mar 2026$7.69M USD-12.5%+2.7%768.9%
NKTXNkarta, Inc.LTM Mar 2026$7.62M USD-49.8%-20.2%—
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$7.36M USD+42.2%—26.1%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$5.66M USD-29.3%+12.5%—
MOLNMolecular Partners AGLTM Mar 2026CHF 4.21M CHF-4.1%-4.6%—
MNOVMediciNova, Inc.LTM Mar 2026$950.91K USD-24.7%+8.9%159.4%
Peer median (excluding SEER) —-5.6%+8.9%62.1%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.17M)(92.97M)(86.28M)(86.6M)(73.6M)
Depreciation & Amortization2.56M3.94M5.58M6.18M7.25M
Deferred Income Tax1.2M0000
Stock-Based Compensation25.93M33.67M34.42M28.21M15.41M
Change in Working Capital(5.87M)(7.09M)(2.72M)(144K)(579K)
Accounts Receivables(2.5M)(2.87M)302K487K277K
Inventory(3.59M)(1.59M)(1.95M)(2.67M)(2.9M)
Accounts Payables1.6M(1.55M)(987K)3.36M1.06M
Other Working Capital(1.38M)(1.07M)(91K)(1.32M)983K
Other Non-Cash Items1.01M1.66M(10.07M)6.25M7.07M
Operating Cash Flow(46.35M)(60.78M)(59.07M)(46.11M)(44.45M)
Capital Expenditures(6.92M)(10.27M)(7.31M)(3.58M)(1.8M)
Acquisitions (Net)163.96M0000
Purchases of Investments(279.96M)(366.27M)(403.09M)(272.93M)(173.17M)
Sales of Investments116M253.65M448.31M342.03M237.81M
Other Investing Activities(163.96M)170K0343K(1.3M)
Investing Cash Flow(170.88M)(122.72M)37.9M65.86M61.55M
Debt Repayment00000
Common Stock Issued102.96M000458K
Common Stock Repurchased(35K)(20K)(13K)(11.82M)(10.2M)
Dividends Paid00000
Other Financing Activities13.71M3.91M465K321K(827K)
Financing Cash Flow116.63M3.89M452K(11.5M)(10.57M)
Effect of Forex Changes00000
Net Change in Cash(100.59M)(179.61M)(20.71M)8.25M6.53M
Free Cash Flow(53.27M)(71.05M)(66.37M)(49.69M)(46.25M)

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.